恒瑞医药：关于获得药物临床试验批准通知书的公告

Core Viewpoint - Heng Rui Medicine announced the approval of clinical trial notifications for three injectable drugs by the National Medical Products Administration [2] Group 1 - The company's subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., received approval for SHR-8068 injection [2] - Shanghai Shengdi Medicine Co., Ltd. also received approval for Adalimumab injection and Bevacizumab injection [2] - The clinical trials for these drugs will commence shortly [2]